ADJUVANT DEVELOPMENT PROGRAM - COVID-19 Supplement

NIH RePORTER · NIH · N01 · $649,995 · view on reporter.nih.gov ↗

Abstract

This study will test a novel antiviral compound (kinase inhibitor) in SARS-CoV2 infected cells. This compound has been shown to inhibit flaviviruses and other CoVs (SARS and MERS).

Key facts

NIH application ID: 10285318
Project number: 272201800049C-P00003-9999-2
Recipient: VIROVAX LLC
Principal Investigator: SUNIL DAVID
Activity code: N01
Funding institute: NIH
Fiscal year: 2020
Award amount: $649,995
Award type: —
Project period: 2018-09-30 → 2023-09-29